Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Cathy Kreimer

Nurse Practitioner Crestview Hills, KY Nurse Practitioner

NPI 1104284496 CMS profile 10532762

351 Centre View Blvd, Crestview Hills, KY 41017

Open in the dashboard

General payments

$5,913

261 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cathy Kreimer of Crestview Hills, KY is reported in the CMS Open Payments database as having received $5,913 across 261 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $967 44
2024 General $978 39
2023 General $1,380 59
2022 General $1,473 76
2021 General $1,115 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cathy Kreimer
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Cathy Kreimer were reported at $967. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Cathy Kreimer Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,115 $135 $40–$426 $132
2022 $1,473 $152 $48–$470 $149
2023 $1,380 $166 $54–$529 $160
2024 $978 $173 $55–$556 $164
2025 $967 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,489 110 payments
  2. Biohaven Pharmaceuticals, Inc. $454 10 payments
  3. Pfizer Inc. $316 16 payments
  4. Amneal Pharmaceuticals LLC $303 20 payments
  5. Biohaven Pharmaceutical Holding Company Ltd. $303 11 payments
  6. Lilly USA, LLC $265 17 payments
  7. Amgen Inc. $230 11 payments
  8. Teva Pharmaceuticals USA, Inc. $227 10 payments
  9. SK Life Science, Inc. $194 9 payments
  10. Lundbeck LLC $162 5 payments
  11. Other $971 42 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,688 260 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $225 1 payment
Products named General payments · program years 2021–2025
  1. UBRELVY $1,545 76 payments
  2. QULIPTA $1,441 44 payments
  3. NURTEC ODT Primary Care $756 21 payments
  4. EMGALITY $262 16 payments
  5. AIMOVIG $247 12 payments
  6. RYTARY $238 17 payments
  7. ZAVZPRET $238 13 payments
  8. REYVOW $225 13 payments
  9. NURTEC ODT Pain $185 14 payments
  10. Leqembi $121 1 payment
  11. Other $1,658 73 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

1,135

Median for Nurse Practitioner: 389

Drug cost

$550,904

Median for Nurse Practitioner: $21,885

Branded share of claims

53.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 137 $180,845
Ubrelvy Ubrogepant Brand 91 $109,523
Emgality Pen Galcanezumab-Gnlm Brand 72 $84,680
Ajovy Autoinjector Fremanezumab-Vfrm Brand 27 $52,561
Qulipta Atogepant Brand 37 $48,844
Aimovig Autoinjector Erenumab-Aooe Brand 23 $32,821
Oxtellar Xr Oxcarbazepine Brand 11 $14,558
Trokendi Xr Topiramate Brand 16 $10,986
Propranolol Hcl Er Propranolol Hcl Brand 66 $2,598
Carbamazepine Er Carbamazepine Brand 28 $2,587

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$34,830

Of which drugs: $26,799

Medicare patients

56

Average age 65

Services billed

5,538

39 women, 17 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 55%
Depression 39%
Diabetes 34%
Ischemic heart disease 29%
Osteoporosis 25%
Chronic kidney disease 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 12 5,400 $26,786

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $251
$251 37 —
Leqembi
  • Eisai Inc. $121
$121 — —
XCOPRI
  • SK Life Science, Inc. $117
$117 — —
UBRELVY
  • AbbVie, Inc. $110
$110 91 —
VYEPTI
  • Lundbeck LLC $52
$52 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

261 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record